Article thumbnail

Targeting TKI-resistance in NSCLC: importance of rebiopsy and molecular diagnostics — A case study

By Jan Stoehlmacher-Williams, Gerhard Ehninger, Dieter R Zimmermann, Sabine Merkelbach-Bruse, Hans-Ulrich Schildhaus and Reinhard Buettner

Abstract

We present the case of a 27 year old woman with widely disseminated metastatic adenocarcinoma of the lung who outlived stage IV diagnosis of NSCLC by more than 4 years. Based on rebiopsy and molecular diagnostics of oncogene dependency, appropriately targeted therapies were successfully employed up to a fifth line oral monotherapy with the ErbB family blocker afatinib for a final 11 months. We stress the importance of rebiopsies, the corresponding selection of targeted therapies, and the observed gain in quality of live even in end stage disease

Topics: Institute of Pathology and Molecular Pathology, 610 Medicine & health, NSCLC, Secondary resistance, Afatinib, EGFR-TKI, Rebiopsy, Fifth line
Publisher: Elsevier
Year: 2013
DOI identifier: 10.1016/j.ctrc.2013.07.001
OAI identifier: oai:www.zora.uzh.ch:86158
Provided by: ZORA

Suggested articles


To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.